The impact of splenectomy on the blood routine examination in a patient with primary myelofibrosis and megalosplenia

doi:10.3877/cma.j.issn.2095-655X.2016.04.005

Abstract

Abstract:

Objective

To explore the impact of splenectomy on the blood routine examination in a patient with primary myelofibrosis (PMF) and megalosplenia.

Methods

Splenectomy was performed on a patient diagnosed with PMF and megalosplenia.Blood routine examinations were dynamically observed and histological examination was performed on the spleen.

Results

After splenectomy, the symptoms of dyspnea, abdominal distension and inappetence improved markedly.Leukocyte increased significantly.The percentage of neutrophils decreased while the percentage of lymphocytes increased.The change of erythrocyte was not obvious.Due to autologous blood transfusion, hemoglobin increased immediately after surgery, and then returned to normal level.Platelet fell to 10×10⁹/L, and then increased gradually to normal level.Histological examination demonstrated that the spleen showed myeloid metaplasia.

Conclusions

Blood routine examination changes significantly after splenectomy is performed on the patient diagnosed with PMF and megalosplenia.The spleen shows certain bone marrow hematopoietic function.After splenectomy, the hematopoietic ability can still meet the need of the body.Thus, splenectomy should be performed on patients with injured respiratory and digestive function due to PMF-caused megalosplenia.

Key words: Primary myelofibrosis, Splenomegaly, Splenectomy, Blood routine examination

Jianjun Gao, Nan Lin, Jiandong Yang, Xianjun Yu. The impact of splenectomy on the blood routine examination in a patient with primary myelofibrosis and megalosplenia[J]. Chinese Journal of Diagnostics(Electronic Edition), 2016, 04(04): 236-239.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2016.04.005

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2016/V04/I04/236

Figures/Tables 7

References 20

[1]	Kröger N,Giorgino T,Scott BL, et al.Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis[J]. Blood, 2015, 125(21): 3347-3350.
[2]	Mohyuddin GR,Yacoub A. Primary myelofibrosis presenting as extramedullary hematopoiesis in a transplanted liver rraft：case report and review of the literature[J]. Case Rep Hematol, 2016: 9515404.
[3]	Maia RC,Bonamino MH,Robaina MC, et al.An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation[J]. Blood Cells Mol Dis, 2015, 55(4): 347-350.
[4]	Pistevou-Gombaki K,Zygogianni A,Kantzou I, et al.Splenic irradi ation as palliative treatment for symptomatic splenomegaly due to secondary myelofibrosis：a multi-institutional experience[J]. J BUON, 2015, 20(4): 1132-1136.
[5]	Webb M,Shibolet O,Halpern Z, et al.Assessment of liver and spleen stiffness in patients with myelofibrosis using fibroscan and shear wave elastography[J]. Ultrasound Q, 2015, 31(3): 166-169.
[6]	Ayl1 M,özcan M,Cengiz Seval G. Ruxolitinib treatment in a patient with primary myelofibrosis resistant to conventional therapies and splenectomy：a case report[J]. Turk J Haematol, 2015, 32(2): 180-183.
[7]	El Fakih R,Popat U. Janus Kinase Inhibitors and Stem Cell Trans plantation in Myelofibrosis[J]. Clin Lymphoma Myeloma Leuk, 2015(15): S34-S42.
[8]	Duenas-Perez AB,Mead AJ.Clinical potential of pacritinib in the treatment of myelofibrosis[J]. Ther Adv Hematol, 2015, 6(4): 186-201.
[9]	Wassie E,Finke C,Gangat N, et al.A compendium of cytogenetic abnormalities in myelofibrosis：molecular and phenotypic correlates in 826 patients[J]. Br J Haematol, 2015, 169(1): 71-76.
[10]	Kröger N. Current challenges in stem cell transplantation in myelofi brosis[J]. Curr Hematol Malig Rep, 2015, 10(4): 344-350.
[11]	Breccia M,Molica M,Colafigli G, et al.Improvement of bone marrow fibrosis with ruxolitinib：will this finding change our perception of the drug？[J]. Expert Rev Hematol, 2015, 8(4): 387-389.
[12]	Markiewicz M,Dzierzak Mietla M,Wieczorkiewicz A, et al.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis[J]. Eur J Haematol, 2016, 96(3): 222-228.
[13]	Hasselbalch HC.Perspectives on the increased risk of second cancer in patients with essential thrombocythemia polycythemia vera and myelofibrosis[J]. Eur J Haematology, 2015, 94(2): 96-98.
[14]	Derlin T,Alchalby H,Bannas P, et al.Assessment of bone marrow inflammation in patients with myelofibrosis：an 18F-fluorodeoxyglucose PET/CT study[J]. Eur J Nucl Med Mol Imaging, 2015, 42(5): 696-705.
[15]	Lane SW,Mullally A. Hit the spleen, JAK！[J]. Blood, 2014, 124(19): 2898-2900.
[16]	Jung CW,Shih LY,Xiao Z, et al.Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis[J]. Leuk Lymphoma, 2015, 56(7): 2067-2074.
[17]	Santos FP,Verstovsek S. Efficacy of ruxolitinib for myelofibrosis[J]. Expert Opin Pharmacother, 2014, 15(10): 1465-1473.
[18]	Gabali AM,Jazaerly T,Chang CC, et al.Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis[J]. Avicenna J Med, 2014, 4(2): 34-36.
[19]	Shimoda K,Takenaka K,Kitanaka A, et al.Clinical aspects of primary myelofibrosis in Japan[J]. Rinsho Ketsueki, 2014, 55(3): 289-294.
[20]	Mughal TI,Vaddi K,Sarlis NJ, et al.Myelofibrosis-associated com plications：pathogenesis, clinical manifestations, and effects on outcomes[J]. Int J Gen Med, 2014(7): 89-101.

时间	白细胞(10⁹/L)	嗜中性粒细胞(%)	淋巴细胞(%)	单核细胞(%)	红细胞(10¹²/L)	血红蛋白(g/L)	血小板(10⁹/L)
术前第3天	5.93	0.47	0.36	0.16	3.39	77.30	57.00
术前第2天	6.67	0.57	0.26	0.15	3.47	81.00	53.00
术前第1天	5.60	0.60	0.29	0.10	3.81	99.10	54.00
手术日	9.14	0.37	0.46	0.15	4.52	106.50	72.00
术后第1天	15.47	0.29	0.51	0.17	4.16	102.70	102.00
术后第2天	17.30	0.44	0.44	0.11	3.89	91.40	44.00
术后第3天	20.00	0.41	0.50	0.09	3.62	86.80	25.00
术后第4天	18.67	0.38	0.46	0.14	3.75	88.00	42.00
术后第5天	14.75	0.30	0.59	0.10	3.78	93.10	10.00
术后第6天	14.31	0.32	0.58	0.09	3.51	85.10	38.00
术后第7天	15.10	0.38	0.43	0.18	3.64	87.00	48.00
术后第8天	18.37	0.37	0.47	0.15	3.54	83.00	66.00
术后第9天	21.58	0.46	0.36	0.20	3.82	88.00	158.00
术后第10天	33.10	0.40	0.52	0.08	3.62	84.90	224.00
术后第11天	27.08	0.26	0.62	0.11	3.42	80.90	334.00
术后第12天	28.79	0.37	0.52	0.10	3.49	82.80	209.00

时间	白细胞(10⁹/L)	嗜中性粒细胞(%)	淋巴细胞(%)	单核细胞(%)	红细胞(10¹²/L)	血红蛋白(g/L)	血小板(10⁹/L)
术前第3天	5.93	0.47	0.36	0.16	3.39	77.30	57.00
术前第2天	6.67	0.57	0.26	0.15	3.47	81.00	53.00
术前第1天	5.60	0.60	0.29	0.10	3.81	99.10	54.00
手术日	9.14	0.37	0.46	0.15	4.52	106.50	72.00
术后第1天	15.47	0.29	0.51	0.17	4.16	102.70	102.00
术后第2天	17.30	0.44	0.44	0.11	3.89	91.40	44.00
术后第3天	20.00	0.41	0.50	0.09	3.62	86.80	25.00
术后第4天	18.67	0.38	0.46	0.14	3.75	88.00	42.00
术后第5天	14.75	0.30	0.59	0.10	3.78	93.10	10.00
术后第6天	14.31	0.32	0.58	0.09	3.51	85.10	38.00
术后第7天	15.10	0.38	0.43	0.18	3.64	87.00	48.00
术后第8天	18.37	0.37	0.47	0.15	3.54	83.00	66.00
术后第9天	21.58	0.46	0.36	0.20	3.82	88.00	158.00
术后第10天	33.10	0.40	0.52	0.08	3.62	84.90	224.00
术后第11天	27.08	0.26	0.62	0.11	3.42	80.90	334.00
术后第12天	28.79	0.37	0.52	0.10	3.49	82.80	209.00

Please choose a citation manager

Content to export